Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Ali A. Rizvi, Djordje S. Popovic, Nikolaos Papanas, Anca Pantea Stoian, Wael Al mahmeed, Amirhossein Sahebkar, Andrej Janez & Manfredi Rizzo. (2022) Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Review of Cardiovascular Therapy 20:7, pages 515-527.
Read now
Read now
Ali A. Rizvi, Ales Linhart, Michal Vrablik, Evangelos Liberopoulos & Manfredi Rizzo. (2022) Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opinion on Drug Safety 21:3, pages 291-293.
Read now
Read now
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo & Ali A. Rizvi. (2019) Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 12:2, pages 129-143.
Read now
Read now
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
Manfredi Rizzo, Angelo Avogaro, Giuseppe Montalto & Ali A Rizvi. (2013) Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opinion on Therapeutic Targets 17:7, pages 739-742.
Read now
Read now
Sana Khan, Saba Khan, Mohammed Imran, Krishna Kolappa Pillai, Mohd Akhtar & Abul Kalam Najmi. (2013) Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus – targeting thrombogenesis. Expert Opinion on Therapeutic Targets 17:6, pages 627-639.
Read now
Read now
Pablo Perez- Martinez, Manfredi Rizzo, Giuseppe Montalto & Jose Lopez- JMiranda. (2013) Postprandial metabolism: from research to clinical practice. Clinical Lipidology 8:4, pages 395-398.
Read now
Read now
Manfredi Rizzo, Gerald H Tomkin, Maria Patti Angelo, Ilenia Pepe, Rosa Valerio Maria, Salvatore Di Rosa, Battista Rini Giovam & Gaetana D Fede. (2011) Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology 6:5, pages 539-547.
Read now
Read now
Danyaal Moin & Anand Rohatgi. (2011) Clinical applications of advanced lipoprotein testing in diabetes mellitus. Clinical Lipidology 6:4, pages 371-387.
Read now
Read now
Nikolaos Papanas, Niki Katsiki, Apostolos I Hatzitolios & Efstratios Maltezos. (2011) Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:10, pages 1457-1461.
Read now
Read now
Manfredi Rizzo, Emanuel R Christ, Giovam Battista Rini, Giatgen A Spinas & Kaspar Berneis. (2008) The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?. Expert Opinion on Pharmacotherapy 9:13, pages 2295-2303.
Read now
Read now
Ramzi A Ajjan & Peter J Grant. (2008) The cardiovascular safety of rosiglitazone. Expert Opinion on Drug Safety 7:4, pages 367-376.
Read now
Read now
Articles from other publishers (43)
Yajnavalka Banerjee, Angelo M. Patti, Rosaria V. Giglio, Marcello Ciaccio, Suhina Vichithran, Shemima Faisal, Anca Panta Stoian, Ali Abbas Rizvi & Manfredi Rizzo. (2023) The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance. Journal of Diabetes and its Complications 37:8, pages 108517.
Crossref
Crossref
Rosaria Vincenza Giglio, Nikolaos Papanas, Ali Abbas Rizvi, Marcello Ciaccio, Angelo Maria Patti, Ioannis Ilias, Anca Pantea Stoian, Amirhossein Sahebkar, Andrej Janez & Manfredi Rizzo. (2022) An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina 58:10, pages 1475.
Crossref
Crossref
Anca Pantea StoianPeter KemplerThomas StulnigAli A. Rizvi & Manfredi Rizzo. (2022) Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. Metabolic Syndrome and Related Disorders 20:3, pages 137-140.
Crossref
Crossref
Miodrag Janić, Manfredi Rizzo, Francesco Cosentino, Anca Pantea Stoian, Mojca Lunder, Mišo Šabović & Andrej Janež. (2022) Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). Diabetes Therapy 13:4, pages 795-810.
Crossref
Crossref
Dragana Nikolic, Angelo M. Patti, Rosaria V. Giglio, Roberta Chianetta, Giuseppa Castellino, Antonio Magán-Fernández, Roberto Citarrella, Nikolaos Papanas, Andrej Janez, Anca Pantea Stoian, Ali A. Rizvi & Manfredi Rizzo. (2022) Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. Diabetes Therapy 13:3, pages 453-464.
Crossref
Crossref
Jelena Vekic, Aleksandra Zeljkovic, Arrigo F. G. Cicero, Andrej Janez, Anca Pantea Stoian, Alper Sonmez & Manfredi Rizzo. (2022) Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina 58:2, pages 299.
Crossref
Crossref
Jelena Vekic, Aleksandra Zeljkovic, Khalid Al Rasadi, Mustafa Cesur, José Silva-Nunes, Anca Pantea Stoian & Manfredi Rizzo. (2022) A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. Metabolites 12:2, pages 108.
Crossref
Crossref
Mihaela Simona Popoviciu, Violeta Nicoleta Marin, Cosmin Mihai Vesa, Simona Diana Stefan, Roxana Adriana Stoica, Cristian Serafinceanu, Emanuele Maria Merlo, Ali A Rizvi, Manfredi Rizzo, Stefan Busnatu & Anca Pantea Stoian. (2022) Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study. Healthcare 10:1, pages 174.
Crossref
Crossref
Stefan-Sebastian Busnatu, Teodor Salmen, Maria-Alexandra Pana, Manfredi Rizzo, Tiziana Stallone, Nikolaos Papanas, Djordje Popovic, Denisa Tanasescu, Dragos Serban & Anca Pantea Stoian. (2022) The Role of Fructose as a Cardiovascular Risk Factor: An Update. Metabolites 12:1, pages 67.
Crossref
Crossref
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Dragos Serban, Anca Pantea Stoian, Kalliopi Pafili, Khalid Al Rasadi, Kanya Rajagopalan, Ali A. Rizvi, Marcello Ciaccio & Manfredi Rizzo. (2022) Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina 58:1, pages 109.
Crossref
Crossref
Manfredi Rizzo. (2021) Molecular Endocrinology and Metabolism in 2021: What’s New. International Journal of Molecular Sciences 22:24, pages 13375.
Crossref
Crossref
Isabella Bonilha, Eric Hajduch, Beatriz Luchiari, Wilson Nadruz, Wilfried Le Goff & Andrei C. Sposito. (2021) The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. Metabolites 11:12, pages 807.
Crossref
Crossref
Jelena Vekic, Aleksandra Zeljkovic, Aleksandra Stefanovic, Rosaria Vincenza Giglio, Marcello Ciaccio & Manfredi Rizzo. (2021) Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents. International Journal of Molecular Sciences 22:22, pages 12409.
Crossref
Crossref
Ali A. Rizvi, Andrej Janez & Manfredi Rizzo. (2021) Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. International Journal of Molecular Sciences 22:22, pages 12311.
Crossref
Crossref
Mihaela Ionescu, Anca Pantea Stoian, Manfredi Rizzo, Dragos Serban, Domenico Nuzzo, Laura Mazilu, Andra Iulia Suceveanu, Ana Maria Dascalu & Irinel Raluca Parepa. (2021) The Role of Endothelium in COVID-19. International Journal of Molecular Sciences 22:21, pages 11920.
Crossref
Crossref
Ali A. Rizvi, Anca Pantea Stoian, Andrej Janez & Manfredi Rizzo. (2021) Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options. Biomedicines 9:11, pages 1579.
Crossref
Crossref
Rosaria Vincenza Giglio, Anca Pantea Stoian, Martin Haluzik, Kalliopi Pafili, Angelo Maria Patti, Ali Abbas Rizvi, Marcello Ciaccio, Nikolaos Papanas & Manfredi Rizzo. (2021) Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1867:8, pages 166148.
Crossref
Crossref
Rosaria Vincenza Giglio, Anca Pantea Stoian, Khalid Al-Rasadi, Maciej Banach, Angelo Maria Patti, Marcello Ciaccio, Ali A. Rizvi & Manfredi Rizzo. (2021) Novel Therapeutical Approaches to Managing Atherosclerotic Risk. International Journal of Molecular Sciences 22:9, pages 4633.
Crossref
Crossref
Rosaria Vincenza Giglio, Giuseppe Carruba, Arrigo F.G. Cicero, Maciej Banach, Angelo Maria Patti, Dragana Nikolic, Letizia Cocciadiferro, Maurizio Zarcone, Giuseppe Montalto, Anca Pantea Stoian, Yajnavalka Banerjee, Ali A. Rizvi, Peter P. Toth & Manfredi Rizzo. (2020) Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. Metabolites 10:11, pages 428.
Crossref
Crossref
Shahin Alizadeh-Fanalou, Ali Nazarizadeh, Fatemeh Alian, Parisa Faraji, Bahareh Sorori & Mohsen Khosravi. (2020) Small dense low-density lipoprotein-lowering agents. Biological Chemistry 401:10, pages 1101-1121.
Crossref
Crossref
Angelo Maria Patti, Ali A Rizvi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Daniela Ligi & Ferdinando Mannello. (2020) Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine 9:4, pages 912.
Crossref
Crossref
Soo Lim, Kuy-Sook Lee, Jie Eun Lee, Ho Seon Park, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Kyong Soo Park, Young Bum Kim & Hak Chul Jang. (2015) Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis 243:1, pages 107-119.
Crossref
Crossref
Ele Ferrannini & Ralph A. DeFronzo. (2015) Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 36:34, pages 2288-2296.
Crossref
Crossref
Tarza J. Siahmansur, Jonathan D. Schofield, Shazli Azmi, Yifen Liu, Paul N. Durrington & Handrean Soran. (2015) Unintended positive and negative effects of drugs on lipoproteins. Current Opinion in Lipidology 26:4, pages 325-337.
Crossref
Crossref
Manfredi Rizzo, Dimitri P. Mikhailidis & Khalid Al-Rasadi. (2014) The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?. Cardiovascular Drugs and Therapy 28:3, pages 205-207.
Crossref
Crossref
Juraj Koska, Aramesh Saremi, Gideon Bahn, Shizuya YamashitaPeter D. Reaven. (2013) The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 36:8, pages 2408-2414.
Crossref
Crossref
Dragana Nikolic, Niki Katsiki, Giuseppe Montalto, Esma Isenovic, Dimitri Mikhailidis & Manfredi Rizzo. (2013) Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. Nutrients 5:3, pages 928-948.
Crossref
Crossref
Erin D Roe, Natalie C Pon, Priscilla Hollander & Philip Raskin. (2013) The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes. Diabetes Management 3:2, pages 145-160.
Crossref
Crossref
Jae Hoon Moon, Hyung Jun Kim, Hyun Min Kim, Ae Hee Yang, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee & Bong Soo Cha. (2012) Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia. Journal of Molecular Endocrinology 49:3, pages 165-174.
Crossref
Crossref
A. P. Agouridis, M. S. Kostapanos, V. Tsimihodimos, C. Kostara, D. P. Mikhailidis, E. T. Bairaktari, A. D. Tselepis & M. S. Elisaf. (2012) Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. International Journal of Clinical Practice 66:9, pages 843-853.
Crossref
Crossref
Philipp A Gerber, Giatgen A Spinas & Kaspar Berneis. (2012) Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?. Diabetes Management 2:1, pages 65-74.
Crossref
Crossref
Iftikhar Alam, Tze Pin Ng & Anis Larbi. (2012) Does Inflammation Determine Whether Obesity Is Metabolically Healthy or Unhealthy? The Aging Perspective. Mediators of Inflammation 2012, pages 1-14.
Crossref
Crossref
B. Charbonnel & B. Cariou. (2011) Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes, Obesity and Metabolism 13:2, pages 99-117.
Crossref
Crossref
Jessica Triay, Rajeev Raghavan, Andrew Day, Parag SinghalGiles Osborne. (2011) Changes in lipid parameters in patients with type 2 diabetes following a switch from rosiglitazone to pioglitazone in primary and secondary care: a prospective, descriptive study. The British Journal of Diabetes & Vascular Disease 11:1, pages 31-37.
Crossref
Crossref
Jeroen P.H. van WijkAndy I.M. HoepelmanEelco J.P. de KoningGeesje Dallinga-ThieTon J. RabelinkManuel Castro Cabezas. (2011) Differential Effects of Rosiglitazone and Metformin on Postprandial Lipemia in Patients With HIV-Lipodystrophy. Arteriosclerosis, Thrombosis, and Vascular Biology 31:1, pages 228-233.
Crossref
Crossref
G. Schernthaner & R. J. Chilton. (2010) Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?. Diabetes, Obesity and Metabolism 12:12, pages 1023-1035.
Crossref
Crossref
M. Rizzo, K. Berneis, S. Koulouris, S. Pastromas, G. B. Rini, D. Sakellariou & A. S. Manolis. (2010) Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. International Journal of Clinical Practice 64:12, pages 1632-1642.
Crossref
Crossref
Manfredi RizzoJelena Vekic, Spyridon Koulouris, Aleksandra Zeljkovic, Zorana Jelic-Ivanovic, Vesna Spasojevic-Kalimanovska, Giovam Battista Rini, Dimitrios Sakellariou, Socrates Pastromas, Dimitri P. Mikhailidis & Antonis S. Manolis. (2010) Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. Angiology 61:6, pages 584-590.
Crossref
Crossref
M. Fisher. (2009) Improving cardiovascular risk - applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. International Journal of Clinical Practice 63:9, pages 1354-1368.
Crossref
Crossref
M. Hanefeld. (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11:8, pages 742-756.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 16:2, pages 189-202.
Crossref
Crossref
Manfredi Rizzo, Ali A. Rizvi, Giovam Battista Rini & Kaspar Berneis. (2008) The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. Acta Diabetologica 46:1, pages 1-11.
Crossref
Crossref
Mark A. Deeg & Meng H. Tan. (2008) Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Research 2008, pages 1-6.
Crossref
Crossref